Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Shepherd

Vascular Surgery Huntsville, AL Medical Doctor

NPI 1346680782 CMS profile 543907

201 Sivley Rd Sw Ste 530, Huntsville, AL 35801

Open in the dashboard

General payments

$13,049

217 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Shepherd of Huntsville, AL is reported in the CMS Open Payments database as having received $13,049 across 217 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,156 34
2024 General $2,011 29
2023 General $1,427 30
2022 General $2,594 54
2021 General $2,685 24
2020 General $1,077 19
2019 General $2,099 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Shepherd
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Benjamin Shepherd were reported at $1,156. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Benjamin Shepherd Vascular Surgery median Middle half National median
2019 $2,099 $796 $226–$2,363 $163
2020 $1,077 $348 $118–$1,110 $114
2021 $2,685 $471 $158–$1,421 $132
2022 $2,594 $725 $222–$2,183 $149
2023 $1,427 $836 $257–$2,440 $160
2024 $2,011 $909 $252–$2,619 $164
2025 $1,156 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $3,163 47 payments
  2. Penumbra, Inc. $2,430 16 payments
  3. Endologix, Inc. $2,143 16 payments
  4. Medtronic, Inc. $1,064 14 payments
  5. Cook Medical LLC $746 13 payments
  6. Silk Road Medical, Inc. $448 9 payments
  7. Terumo Medical Corporation $442 8 payments
  8. Kerecis Limited $355 8 payments
  9. Inari Medical, Inc. $300 5 payments
  10. Imperative Care, INc $188 3 payments
  11. Other $1,769 78 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,022 206 payments
  2. Travel and Lodging $1,805 8 payments
  3. Education $221 3 payments
Products named General payments · program years 2019–2025
  1. Indigo System $2,398 13 payments
  2. Alto Abdominal Stent Graft System $1,457 12 payments
  3. EXCLUDER AAA Endoprosthesis $936 7 payments
  4. IN.PACT Admiral $908 11 payments
  5. Torus Stent Graft System $620 3 payments
  6. ENDOCROSS Device $609 2 payments
  7. Azur CX Detachable $425 7 payments
  8. VIABAHN VBX Balloon Expandable Endoprosthesis $365 4 payments
  9. ENROUTE Transcarotid Stent $345 7 payments
  10. ENROUTE Transcarotid Neuroprotection System $345 7 payments
  11. Other $7,651 197 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

187

Median for Vascular Surgery: 122

Drug cost

$22,888

Median for Vascular Surgery: $14,135

Branded share of claims

93%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 16 $13,808
Brilinta Ticagrelor Brand 17 $7,280
Clopidogrel Clopidogrel Bisulfate Brand 72 $832
Cilostazol Generic 13 $467
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 57 $403
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 12 $99

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 111 billing codes

Paid by Medicare

$204,830

Medicare's payments for the services billed

Medicare patients

462

Average age 75

Services billed

1,765

217 women, 245 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 57%
Chronic kidney disease 49%
Diabetes 48%
Heart failure 37%
Atrial fibrillation 34%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record